Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could ...

The small, 48-subject study – published in ... in Boston is running a four-week pilot study comparing Eli Lilly's dual GIP/GLP-1 tirzepatide to placebo in around 20 AUD patients, focusing ...

The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes.

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply of the upcoming oral options will be the sector’s next great challenge.

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 ...

Some analysts expect the market for GLP-1s to be worth more ... But so-called small molecule pills will at least be easier for Eli Lilly to manufacture than injections. In January, Eli Lilly ...